ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A recent study has shown that imatinib, a BCR-ABL inhibitor used for the therapy of chronic myeloid leukemia (CML), downregulates p21 expression at both mRNA and protein levels in sensitive CML cells, while resistant CML cells exhibit increased p21 expression [73].